Selected research
Market Structure
Global Gastric Carcinomas Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Gastric Carcinomas Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Gastric Carcinomas Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Gastric Carcinomas Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gastric Carcinomas Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Gastric Carcinomas Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Gastric Carcinomas Drugs include Chiatai Tianqing, Fujian Haiwang Fuyao Pharmacy Limited Company, Merck & Co, Novo Nordisk, Taiho Pharmaceutical, Bayer, Jiangsu Hengrui Medicine Company Limited, Pfizer and Eli Lilly and Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Gastric Carcinomas Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Gastric Carcinomas Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Gastric Carcinomas Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Gastric Carcinomas Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Gastric Carcinomas Drugs Segment by Company
Chiatai Tianqing
Fujian Haiwang Fuyao Pharmacy Limited Company
Merck & Co
Novo Nordisk
Taiho Pharmaceutical
Bayer
Jiangsu Hengrui Medicine Company Limited
Pfizer
Eli Lilly and Company
Roche
Qilu Pharma
Shandong New Era Hotel Pharmaceutical Industry Limited Company
Gastric Carcinomas Drugs Segment by Type
First Line Treatment
Second Line Treatment
Three Line Treatment
Gastric Carcinomas Drugs Segment by Application
Hospital
Clinic
Others
Gastric Carcinomas Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Carcinomas Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Carcinomas Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Carcinomas Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Gastric Carcinomas Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastric Carcinomas Drugs industry.
Chapter 3: Detailed analysis of Gastric Carcinomas Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastric Carcinomas Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- First Line Treatment
- Second Line Treatment
- Three Line Treatment
Applications
- Hospital
- Clinic
- Others
Companies covered
- Chiatai Tianqing
- Fujian Haiwang Fuyao Pharmacy Limited Company
- Merck & Co
- Novo Nordisk
- Taiho Pharmaceutical
- Bayer
- Jiangsu Hengrui Medicine Company Limited
- Pfizer
- Eli Lilly and Company
- Roche
- Qilu Pharma
- Shandong New Era Hotel Pharmaceutical Industry Limited Company
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Gastric Carcinomas Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 First Line Treatment
- 1.2.3 Second Line Treatment
- 1.2.4 Three Line Treatment
- 1.3 Market Analysis by Application
- 1.3.1 Global Gastric Carcinomas Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Gastric Carcinomas Drugs Growth Trends by Region
- 1.5.1 Global Gastric Carcinomas Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Gastric Carcinomas Drugs Market Size by Region (2021-2026)
- 1.5.3 Gastric Carcinomas Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Gastric Carcinomas Drugs Market Dynamics
- 2.1 Gastric Carcinomas Drugs Industry Trends
- 2.2 Gastric Carcinomas Drugs Industry Drivers
- 2.3 Gastric Carcinomas Drugs Industry Opportunities and Challenges
- 2.4 Gastric Carcinomas Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Gastric Carcinomas Drugs Revenue by Company (2021-2026)
- 3.2 Global Gastric Carcinomas Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Gastric Carcinomas Drugs Key Company Head office and Area Served
- 3.4 Global Gastric Carcinomas Drugs Company, Product Type & Application
- 3.5 Global Gastric Carcinomas Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Gastric Carcinomas Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Gastric Carcinomas Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Gastric Carcinomas Drugs Tier 1, Tier 2, and Tier 3
4 Gastric Carcinomas Drugs Market by Type
- 4.1 Global Gastric Carcinomas Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Gastric Carcinomas Drugs Market Size by Type (2021-2032)
- 4.3 Global Gastric Carcinomas Drugs Market Size Share by Type (2021-2032)
5 Gastric Carcinomas Drugs Market by Application
- 5.1 Global Gastric Carcinomas Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Gastric Carcinomas Drugs Market Size by Application (2021-2032)
- 5.3 Global Gastric Carcinomas Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Chiatai Tianqing
- 6.1.1 Chiatai Tianqing Company Information
- 6.1.2 Chiatai Tianqing Business Overview
- 6.1.3 Chiatai Tianqing Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Chiatai Tianqing Gastric Carcinomas Drugs Product Portfolio
- 6.1.5 Chiatai Tianqing Recent Developments
- 6.2 Fujian Haiwang Fuyao Pharmacy Limited Company
- 6.2.1 Fujian Haiwang Fuyao Pharmacy Limited Company Company Information
- 6.2.2 Fujian Haiwang Fuyao Pharmacy Limited Company Business Overview
- 6.2.3 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Product Portfolio
- 6.2.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Developments
- 6.3 Merck & Co
- 6.3.1 Merck & Co Company Information
- 6.3.2 Merck & Co Business Overview
- 6.3.3 Merck & Co Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Merck & Co Gastric Carcinomas Drugs Product Portfolio
- 6.3.5 Merck & Co Recent Developments
- 6.4 Novo Nordisk
- 6.4.1 Novo Nordisk Company Information
- 6.4.2 Novo Nordisk Business Overview
- 6.4.3 Novo Nordisk Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Novo Nordisk Gastric Carcinomas Drugs Product Portfolio
- 6.4.5 Novo Nordisk Recent Developments
- 6.5 Taiho Pharmaceutical
- 6.5.1 Taiho Pharmaceutical Company Information
- 6.5.2 Taiho Pharmaceutical Business Overview
- 6.5.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Product Portfolio
- 6.5.5 Taiho Pharmaceutical Recent Developments
- 6.6 Bayer
- 6.6.1 Bayer Company Information
- 6.6.2 Bayer Business Overview
- 6.6.3 Bayer Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Bayer Gastric Carcinomas Drugs Product Portfolio
- 6.6.5 Bayer Recent Developments
- 6.7 Jiangsu Hengrui Medicine Company Limited
- 6.7.1 Jiangsu Hengrui Medicine Company Limited Company Information
- 6.7.2 Jiangsu Hengrui Medicine Company Limited Business Overview
- 6.7.3 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Product Portfolio
- 6.7.5 Jiangsu Hengrui Medicine Company Limited Recent Developments
- 6.8 Pfizer
- 6.8.1 Pfizer Company Information
- 6.8.2 Pfizer Business Overview
- 6.8.3 Pfizer Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Pfizer Gastric Carcinomas Drugs Product Portfolio
- 6.8.5 Pfizer Recent Developments
- 6.9 Eli Lilly and Company
- 6.9.1 Eli Lilly and Company Company Information
- 6.9.2 Eli Lilly and Company Business Overview
- 6.9.3 Eli Lilly and Company Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Eli Lilly and Company Gastric Carcinomas Drugs Product Portfolio
- 6.9.5 Eli Lilly and Company Recent Developments
- 6.10 Roche
- 6.10.1 Roche Company Information
- 6.10.2 Roche Business Overview
- 6.10.3 Roche Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Roche Gastric Carcinomas Drugs Product Portfolio
- 6.10.5 Roche Recent Developments
- 6.11 Qilu Pharma
- 6.11.1 Qilu Pharma Company Information
- 6.11.2 Qilu Pharma Business Overview
- 6.11.3 Qilu Pharma Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Qilu Pharma Gastric Carcinomas Drugs Product Portfolio
- 6.11.5 Qilu Pharma Recent Developments
- 6.12 Shandong New Era Hotel Pharmaceutical Industry Limited Company
- 6.12.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Company Information
- 6.12.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Business Overview
- 6.12.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Product Portfolio
- 6.12.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Developments
7 North America
- 7.1 North America Gastric Carcinomas Drugs Market Size (2021-2032)
- 7.2 North America Gastric Carcinomas Drugs Market Size by Type
- 7.2.1 North America Gastric Carcinomas Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Gastric Carcinomas Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Gastric Carcinomas Drugs Market Share by Type (2021-2032)
- 7.3 North America Gastric Carcinomas Drugs Market Size by Application
- 7.3.1 North America Gastric Carcinomas Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Gastric Carcinomas Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Gastric Carcinomas Drugs Market Share by Application (2021-2032)
- 7.4 North America Gastric Carcinomas Drugs Market Size by Country
- 7.4.1 North America Gastric Carcinomas Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Gastric Carcinomas Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Gastric Carcinomas Drugs Market Size (2021-2032)
- 8.2 Europe Gastric Carcinomas Drugs Market Size by Type
- 8.2.1 Europe Gastric Carcinomas Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Gastric Carcinomas Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Gastric Carcinomas Drugs Market Share by Type (2021-2032)
- 8.3 Europe Gastric Carcinomas Drugs Market Size by Application
- 8.3.1 Europe Gastric Carcinomas Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Gastric Carcinomas Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Gastric Carcinomas Drugs Market Share by Application (2021-2032)
- 8.4 Europe Gastric Carcinomas Drugs Market Size by Country
- 8.4.1 Europe Gastric Carcinomas Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Gastric Carcinomas Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Gastric Carcinomas Drugs Market Size (2021-2032)
- 9.2 China Gastric Carcinomas Drugs Market Size by Type
- 9.2.1 China Gastric Carcinomas Drugs Market Size by Type (2021-2026)
- 9.2.2 China Gastric Carcinomas Drugs Market Size by Type (2027-2032)
- 9.2.3 China Gastric Carcinomas Drugs Market Share by Type (2021-2032)
- 9.3 China Gastric Carcinomas Drugs Market Size by Application
- 9.3.1 China Gastric Carcinomas Drugs Market Size by Application (2021-2026)
- 9.3.2 China Gastric Carcinomas Drugs Market Size by Application (2027-2032)
- 9.3.3 China Gastric Carcinomas Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Gastric Carcinomas Drugs Market Size (2021-2032)
- 10.2 Asia Gastric Carcinomas Drugs Market Size by Type
- 10.2.1 Asia Gastric Carcinomas Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Gastric Carcinomas Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Gastric Carcinomas Drugs Market Share by Type (2021-2032)
- 10.3 Asia Gastric Carcinomas Drugs Market Size by Application
- 10.3.1 Asia Gastric Carcinomas Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Gastric Carcinomas Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Gastric Carcinomas Drugs Market Share by Application (2021-2032)
- 10.4 Asia Gastric Carcinomas Drugs Market Size by Country
- 10.4.1 Asia Gastric Carcinomas Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Gastric Carcinomas Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Gastric Carcinomas Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Gastric Carcinomas Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Gastric Carcinomas Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst